IngredientsHyphomycetes are a form classification of fungi, part of what has often been referred to as fungi imperfecti, Deuteromycota, or anamorphic fungi. Hyphomycetes lack closed fruit bodies and are often referred to as moulds (or molds). As a group, they are defined not by shared evolutionary ancestry but by a common morphological trait: their conidia (asexual spores) are produced freely on exposed conidiophores rather than within enclosed structures such as perithecia or cleistothecia. This makes "Hyphomycetes" a form-class — a category of practical convenience rather than a phylogenetically coherent taxon.
Most hyphomycetes are now mainly assigned to the Ascomycota on the basis of genetic connections made by life-cycle studies or by phylogenetic analysis of DNA sequences; some remain unassigned phylogenetically. There are also some basidiomycete species, with aquatic presence noted in certain Corticiaceae and Urediniomycetes. Although no longer considered a phylogenetically defined taxon, the prevalence of hyphomycete forms in nature, the built environment, and laboratories means that identification of members of this group remains of practical importance.
The group spans an enormous ecological and chemical diversity. Fusarium fungi belong to a large genus of filamentous fungi, part of a group often referred to as hyphomycetes, widely distributed in soil and associated with plants. Many food-borne fungi are also hyphomycetes.
Among the most pharmacologically and commercially studied hyphomycetes are the entomopathogenic (insect-killing) genera. Well-known entomogenous hyphomycetes are classified in Beauveria, Metarhizium, and Tolypocladium; famous anamorphic generic names such as Akanthomyces, Gibellula, Hirsutella, Hymenostilbe, and Isaria are now subsumed in genera formerly considered sexual, such as Cordyceps, Ophiocordyceps, and Torubiella under fungal single-name nomenclature.
Beauveria is a genus of cosmopolitan, soil-borne entomopathogenic fungi belonging to the family Cordycipitaceae within the Ascomycota phylum, characterized by their asexually reproducing hyphomycetes that primarily act as necrotrophic pathogens of arthropods, infecting over 700 insect species worldwide. The genus comprises approximately 25 described species, with Beauveria bassiana being the most prominent and widely studied due to its broad host range and historical association with muscardine disease in silkworms.
The genus was included in phylum Deuteromycotina (Fungi Imperfecti), class Hyphomycetes, order Moniliales, family Moniliaceae. This assumption was hampered by the recent discoveries of Cordyceps teleomorphs associated with Beauveria. The anamorph genera of Cordyceps are hyphomycetes with conidiogenous cells that are hyaline to brightly coloured and produce conidia in dry chains or slimy drops.
Aquatic hyphomycetes, a group of nonzoosporic aquatic fungi, have not been extensively surveyed as antibiotic producers, perhaps owing to their ecological peculiarities. In contrast to the majority of terrestrial fungi, aquatic hyphomycetes show a variety in characteristic conidial shapes, which range from simple rounded spores to filiform and branched triradiate or tetraradiate spores. Aquatic hyphomycetes, members of "Fungi Imperfecti," are prolific producers of secondary metabolites useful in medicinal, industrial, and agricultural areas; they are the major microbial element in aquatic ecosystems, occurring as active colonizers of submerged decaying leaf litter.
Acremonium fungi constitute one of the greatest and most complex genera in Hyphomycetes, comprising 130 species of marine and terrestrial origin. The past decades have witnessed substantial chemical and biological investigations on the diverse secondary metabolites from Acremonium species; to date, over 600 compounds with abundant chemical types as well as a wide range of bioactivities have been obtained from this genus.
Tolypocladium inflatum is an ascomycete fungus originally isolated from a Norwegian soil sample that, under certain conditions, produces the immunosuppressant drug ciclosporin. In its sexual stage (teleomorph) it is a parasite on scarab beetles. In its asexual stage (anamorph) it is a white mold that grows on soil; it is much more commonly found in its asexual stage, and this is the stage that was originally given the name Tolypocladium inflatum.
Hyphomycetes occupy virtually every terrestrial and aquatic ecosystem on Earth. Terrestrial genera such as Beauveria and Metarhizium are predominantly soil-dwelling. Beauveria is a globally distributed genus of soil-borne entomopathogenic hyphomycetes of interest as a model system for the study of entomopathogenesis and the biological control of pest insects. The fungus Metarhizium anisopliae is a natural component of soil flora worldwide and is a causal agent of the green muscardine diseases of insects.
Beauveria species exhibit versatile lifestyles, functioning not only as insect killers but also as saprophytes in soil and occasional endophytes in plants. Aquatic hyphomycetes, by contrast, colonize freshwater streams, particularly in association with submerged leaf litter and root systems of riparian plants. Roots of aquatic and riparian plants from streams and their catchment areas — for example, in the Nainital, Kumaon Himalayas region of India — have yielded root endophytic freshwater hyphomycetes.
Paecilomyces, another hyphomycetous genus, is a common saprobic filamentous fungus found in a wide range of habitats, including soils, forests, grassland, deserts, sediments, and even sewage sludge.
Because Hyphomycetes as a formal grouping was not codified scientifically until the modern era of mycology, traditional medical systems did not identify these fungi by that name. However, several key genera that fall within this morphological class have deep roots in traditional healing practices, and the organisms themselves — identified by their macroscopic effects — were used for centuries before their fungal nature was understood.
Mushrooms have been used as traditional medicine for millennia, as described extensively in the literature. Several hyphomycetous fungi were central to this tradition. The genus Isaria (now taxonomically reclassified into Cordyceps and Ophiocordyceps), whose asexual morphs are classic hyphomycetes, was used in Traditional Chinese Medicine for centuries as a tonic for vitality, respiratory function, and male reproductive health.
Nucleosides are important for regulating diverse physiological processes in humans and for preventing or treating diseases; nucleosides, including adenosine, cordycepin, and N6-(2-hydroxyethyl)-adenosine (HEA), represent the major active components in Cordyceps sensu lato. The asexual morphs of Cordyceps — which include historically named hyphomycete genera such as Hirsutella, Isaria, and Beauveria — were the forms most commonly encountered in soil and on cadaverized insects, and their fruiting bodies were collected in high-altitude grasslands (notably in Tibet and Sichuan) and prepared as decoctions or powders.
In Ancient Egypt, mouldy bread was applied to wound infection. While the specific fungi responsible for this mould were not identified by ancient practitioners, hyphomycetous moulds — including genera now classified under Hyphomycetes — were the predominant organisms present. The antibacterial metabolites produced by such moulds (foreshadowing the later discovery of penicillin and cephalosporins) underpinned the empirical effectiveness of these applications.
The association of Beauveria bassiana with silkworm disease (muscardine) was noted in sericulture-based cultures of East Asia and southern Europe for centuries before its fungal etiology was demonstrated. The white, chalky appearance of infected insect cadavers gave rise to the name "muscardine" (from the French for the musk candy it resembled). The Italian naturalist Agostino Bassi demonstrated in 1835 that this disease was caused by a living parasitic fungus — a landmark moment in the history of germ theory — and the organism was later named Beauveria bassiana in his honour.
Secondary metabolites from fungi can be synthesized by using several enzymatic pathways, but the most prominent ones are the polyketide, non-ribosomal peptide (NRP), terpenoid, and alkaloid pathways; in addition, there is an alternative known as a hybrid pathway.
Cyclosporine was first isolated and structurally identified as a cyclic undecapeptide metabolite from the insect-pathogenic and soil-dwelling fungus Tolypocladium inflatum in the early 1970s. The cyclopeptide cyclosporin A was first isolated from the filamentous fungus Tolypocladium inflatum showing antifungal activity and was later developed as an immunosuppressant drug.
Cyclosporin A (CsA) was developed and approved as an immunosuppressant drug used in organ transplantation in 1983, and more than 30 analogs of CsA have been identified with different biological activities, including immunosuppressive, antifungal, antiviral, and antiparasitic properties.
The biosynthesis of cyclosporin A is complex. The biosynthetic gene cluster responsible for cyclosporin biosynthesis is suggested to include 12 genes encoding enzymes, including the nonribosomal peptide synthetase (NRPS) (SimA) responsible for assembling the 11 amino acid substrates of cyclosporine, and a polyketide synthase (PKS) (SimG) to mediate the production of the unusual amino acid (4R)-4-[(E)-2-butenyl]-4-methyl-L-threonine (Bmt).
Ciclosporin A works by targeting and binding with human cyclophilin A; this cyclosporine–cyclophilin binding inhibits calcineurin and effectively inhibits the human immune system. Without calcineurin, the activity of nuclear factor of activated T-cells and transcription regulators of IL-2 in T-lymphocytes is blocked.
The cephalosporins, a class of β-lactam antibiotics, were first discovered in Acremonium by the Italian pharmacologist Giuseppe Brotzu in 1948. The discovery of Cephalosporium acremonium (later reclassified as Acremonium chrysogenum) began in 1948 when Italian scientist Giuseppe Brotzu isolated it from a sewage outfall off the Sardinian coast; Brotzu observed that crude filtrates from this fungus exhibited antibacterial activity, particularly against Salmonella typhi, the bacterium responsible for typhoid fever. Researchers at the University of Oxford, including Guy Newton and Edward Abraham, later isolated specific compounds from the fungal culture, identifying Cephalosporin C, which shared a structural similarity with penicillin, featuring a beta-lactam ring.
Cephalosporins are a class of beta-lactam antibiotics that work by interfering with the formation of bacterial cell walls, leading to bacterial death; they are effective against a wide range of bacterial infections, earning them the designation of "broad-spectrum" antibiotics.
The metabolites from Beauveria sp. can be divided into three main kinds: alkaloids (tenellin, bassiatin, pyridovercin, pyridomacrolidin, ilicicdin H), cyclodepsipeptides (beauvericins, allobeauvericins, bassianolides, beauveriolides), and benzoquinone (oosporein) — many of them exert insecticidal, anthelminthic, synergistic antifungal, antibacterial, antiviral, and cytotoxic activities.
Beauvericin (BEA) is an emerging mycotoxin produced by the entomopathogenic fungus Beauveria bassiana, originally studied for its potential use as a pesticide; BEA is now considered a molecule of interest for its possible use in diverse biotechnological applications in the pharmaceutical industry and medicine.
SPME-GC/MS analysis of volatile organic compounds (VOCs) from B. bassiana revealed the presence of ethanol, butanal (2-methyl), 2,4-dimethyl-1-heptene, octane (4-methyl), and β-elemene as the dominant bioactive compounds.
HEA was the first calcium antagonist derived from biological sources and can be used as an inotropic agent; recent studies have revealed HEA has various biological activities. For example, it can inhibit the proliferation of tumour cells in vitro, including Lewis lung cancer and K562 erythroleukemia cells. HEA regulates cerebral and coronary circulation and appears to function as a sedative in pharmacological tests; the mechanism underlying the analgesic activity of HEA differs from opioids.
Testing for the presence of Ca2+ antagonists and inotropic agents in the water–ethanol extracts from mycelia of 17 Cordyceps species and 6 Isaria species (hyphomycetous genera) using the left atrium of a guinea pig heart in an in vitro system found that the mycelial extracts from two Cordyceps species and four Isaria species were highly active for inotropic effects; the active substance was identified as HEA.
The study on isolation and structural determination of antimicrobial compounds from Anguillospora longissima and A. crassa has resulted in the discovery of some novel metabolites; quinaphthin, a new antimicrobial compound, has also been described from the aquatic hyphomycetes Helicoon richonis.
The chemical structures of secondary metabolites from Acremonium fungi can mainly be classified into four types: terpenoids (46%), polyketides (24%), peptides (17%), and others (13%) consisting of steroids, amides, and alkaloids; among 115 recently reported new compounds, terpenoids predominantly accounted for 42%, while polyketides, peptides, and other types accounted for 20%, 29%, and 9%, respectively. Nearly 37.3% of these compounds showed broad-spectrum biological activities, including insecticidal, antibacterial, cytotoxic, enzyme inhibition, antiviral, anti-inflammatory, antioxidant, and antimalarial activities; notably, antibacterial (35.6%), cytotoxic (35.6%), and anti-inflammatory (10.9%) represent the top three bioactivities.
Polyketides are conjugated by polyketide synthases (PKSs), multi-domain enzymes that catalyze the sequential condensation of acetyl-CoA and malonyl-CoA in the polyketide pathway; these enzymes synthesize exceptionally diverse compounds, which include aflatoxins, lovastatins, and tetracycline (antibiotics). In the NRPs pathway, non-ribosomal peptides are synthesized using NRP synthetases; the synthesis of cyclic peptides, like penicillin and cyclosporin, commonly recognized for their antibacterial and immunosuppressive properties, is attributed to these multi-modular enzymes.
Annual reviews of fungal secondary metabolites document the pace of compound discovery across the broader hyphomycete class. Structural categorisation of 2024 fungal natural product discoveries showed that terpenoids were the most abundant class (40%, 362 compounds), followed by polyketides (31%, 284), alkaloids (12%, 108), peptides (8%, 75), glycosides (6%, 50), and steroids (3%, 28).
It is critical to distinguish between (a) pharmaceutical drugs derived from hyphomycetes and approved through rigorous clinical trials; (b) research-stage compounds under investigation from these fungi; and (c) the use of whole-mycelium or extract preparations as dietary supplements, which generally lack robust human clinical evidence. The following sections address each area.
Discovery of cyclosporine in 1971 began a new era in immunopharmacology; it was the first immunosuppressive drug that allowed selective immunoregulation of T cells without excessive toxicity. Cyclosporine was first investigated as an anti-fungal antibiotic, but its spectrum was too narrow to be of any clinical use; J. F. Borel discovered its immunosuppressive activity in 1976.
This body of evidence is the strongest associated with any hyphomycete-derived compound. Cyclosporin A has undergone decades of randomized controlled trials for organ transplantation, rheumatoid arthritis, psoriasis, and nephrotic syndrome, and is approved by major regulatory authorities worldwide. The cyclosporin A (cycloundecapeptide) was initially extracted from the insect pathogen Tolypocladium inflatum and is well documented for its antifungal, immunosuppressant, anti-inflammatory, and antiparasitic potential. Cyclosporine has unwanted side effects, notably nephrotoxicity.
Evidence strength: Cyclosporin A is a licensed pharmaceutical with extensive Level I clinical evidence (multiple RCTs, systematic reviews, long-term post-marketing surveillance). This is distinct from any dietary supplement application.
The development of cephalosporin antibiotics significantly advanced the treatment of various bacterial diseases, including pneumonia, skin infections, and urinary tract infections; the first cephalosporin, Cephalothin, became available for clinical use in the United States in 1964, and since then multiple generations of cephalosporins have been developed, each with varying activity against different types of bacteria, expanding their utility in modern medicine.
Evidence strength: Like cyclosporin A, cephalosporins are licensed pharmaceutical agents with extensive clinical evidence. This is not a dietary supplement application.
Both living mycelium discs (5 mm) and crude extracts of endophytic freshwater hyphomycetes showed considerable inhibitory properties against all five tested bacterial strains in laboratory assays; on the basis of these findings, it was concluded that endophytic freshwater aquatic hyphomycetous fungi might be an important source of active pharmacologic compounds. However, the commercial implication for the production of desirable antimicrobial compounds by the endophytic fungi still remains a future goal.
Screening studies of aquatic hyphomycetes against plant and human pathogens have reported positive results. In a preliminary antibacterial assay, Campylospora parvula showed a maximum zone of inhibition of 28 mm against X. phaseoli, while Tetracladium setigerum showed a maximum zone of inhibition of 28 mm against Xanthomonas campestris. The minimum inhibitory concentration (MIC) of C. aquaticum was recorded at 50 µg/ml against F. oxysporum and 25 µg/ml against F. solani and R. solani, while the MIC of B. rhombica was 50 µg/ml against all the test fungi; the minimum inhibitory concentration and activity index of hyphomycetous extracts indicated their potential was more or less equivalent to that of carbendazim, a commercial fungicide.
Evidence strength: Entirely preliminary. All studies are in vitro laboratory assays. No human clinical trials exist for aquatic hyphomycete extracts as antimicrobial dietary supplements.
Species of Helicomyces, Helicosporium, and Helicoma have been reported to produce natural products with antibacterial, anticancer, and anti-diabetic activities. One study reported two novel compounds in Tubeufia rubra, one of which reverses multidrug resistance of tumor cell lines to Doxorubicin.
Reviews of endophytic fungi — many of which are hyphomycetes — emphasize their capacity to exhibit antioxidant, anti-inflammatory, antimicrobial, and anticancer effects, and highlight how the compounds interact with cellular receptors, signaling pathways, and gene expression.
Regarding beauvericin and related cyclodepsipeptides, beauvericin (BEA), originally studied for its potential use as a pesticide, is now considered a molecule of interest for its possible use in diverse biotechnological applications in the pharmaceutical industry and medicine, and has been reviewed as a potential therapeutic agent for multiple diseases.
Evidence strength: Preliminary. The majority of anticancer data from hyphomycete species are cell-line and animal studies. Robust human clinical trials are absent. The compounds showing promise (such as those from Tubeufia, Helicoma, and Beauveria) have not been evaluated in dietary supplement settings in human subjects.
HEA (N6-(2-hydroxyethyl)-adenosine), produced by hyphomycetous anamorphs within the Cordyceps complex, has various biological activities, including inhibiting the proliferation of tumour cells in vitro, including Lewis lung cancer and K562 erythroleukemia cells.
The broader category of Cordyceps-related hyphomycetous supplements (including mycelial powders from Isaria tenuipes, Cordyceps militaris mycelia, and related species) has been studied in small human trials for exercise performance and fatigue. However, the evidence base is limited in quality and quantity. Some species are included in traditional medicine but lack evidence as to any health benefit.
Evidence strength: Preliminary to moderate for specific nucleoside effects (primarily in vitro and animal studies); limited human evidence for whole mycelial preparations. No large-scale RCTs confirm clinical benefit of hyphomycetous fungi as dietary supplements for immunomodulation in otherwise healthy populations.
Several secondary metabolites from hyphomycetes show antifungal activity in laboratory settings. Four new tetramic acid derivatives (talaroconvolutins A–D) were isolated from the hyphomycetous genus Talaromyces; antifungal activity against pathogenic fungi including Aspergillus fumigatus, A. niger, Cryptococcus albicans, and C. neoformans was determined, and results showed that talaroconvolutins B and C inhibited the growth of A. fumigatus, A. niger, and C. albicans.
Evidence strength: In vitro only. No human clinical trials for antifungal dietary supplementation with hyphomycete extracts.
Beauveria and Metarhizium species show some promise as biological control agents against pest insects. This area has a strong applied evidence base, though it is relevant to agriculture rather than human health directly. Results demonstrated that efficient isolates of B. bassiana can be potentially used as biocontrol agents against several bacteria, especially Gram-positive ones.
Mushroom dietary supplements, commonly made from powdered or extracted fruit bodies or mycelium, are marketed for various health benefits but lack sufficient scientific evidence for their safety or effectiveness, and their quality can vary due to inconsistent processing and labeling.
Where hyphomycetous fungi appear in the dietary supplement market, they do so most commonly in the following forms:
Alternatively, filamentous fungi, which can be easier to produce than macrofungi, play an active role in the synthesis of some bioactive compounds that are also important for health, as well as being rich in protein content.
The available literature does not provide standardized dosing recommendations for hyphomycete-derived preparations as dietary supplements. The following figures are drawn exclusively from specific scientific sources:
No clinical dose–response data from human trials with hyphomycete-specific dietary supplements could be identified in the authoritative sources searched. This reflects the early-stage nature of translation from laboratory discovery to clinical application.
Infections of humans by fungi of the genus Acremonium are rare, but clinical manifestations of hyalohyphomycosis caused by Acremonium may include arthritis, osteomyelitis, peritonitis, endocarditis, pneumonia, cerebritis, and subcutaneous infection. These infections typically occur in immunocompromised individuals rather than in healthy people.
Although B. bassiana is used as a biological control agent for insect pests as an alternative to chemical insecticides and is considered to be non-pathogenic to vertebrates, a small number of patients with keratitis caused by B. bassiana have been reported.
Several secondary metabolites of hyphomycetes are recognized mycotoxins at high concentrations. Beauvericin (BEA) is an emerging mycotoxin produced by the entomopathogenic fungus Beauveria bassiana, originally studied for its potential use as a pesticide. The dual nature of beauvericin — simultaneously studied for pharmaceutical potential and flagged as a mycotoxin — illustrates the complexity of safety assessment for hyphomycete-derived products. The mycotoxin oosporein has also been identified as a relevant secondary metabolite in certain Beauveria species.
Cyclosporine has unwanted side effects, notably nephrotoxicity. This is a well-documented, clinically significant adverse effect of the hyphomycete-derived pharmaceutical cyclosporin A, occurring even at therapeutic doses and requiring monitoring of renal function in all patients receiving the drug.
As a substrate and inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme and P-glycoprotein transporter system, cyclosporin A has numerous documented interactions with other medications. Co-administration with nephrotoxic drugs, CYP3A4 inhibitors (such as azole antifungals, macrolide antibiotics, and certain calcium channel blockers), and CYP3A4 inducers (such as rifampicin and anticonvulsants) significantly alters its pharmacokinetics and toxicity profile. These interactions are relevant in the pharmaceutical context but would also apply if any cyclosporin-containing preparation were consumed as a supplement.
Analysis of numerous fungal supplements has found that they vary tremendously in the amount of medicinal ingredients included, which are believed to be important agents of healing, depending on whether or not they are powders derived from grain-grown mycelium, water-soluble or alcohol extracts, or dual extracts from whole fruiting bodies.
Regarding the safety of hyphomycetous biocontrol agents in the broader environment, regulatory assessments and peer-reviewed safety reviews have been conducted for both Beauveria bassiana and Metarhizium anisopliae. Entomopathogenic fungi (EPF)-based biopesticides are increasingly being recognized as eco-friendly yet potent options for insect pest management, given their minimal effect on non-target species, compatibility with other biological control interventions, and ability to persist in the ecosystem.
Endophytic freshwater aquatic hyphomycetous fungi might be an important source of active pharmacologic compounds; however, the commercial implication for the production of desirable antimicrobial compounds by endophytic fungi still remains a future goal.
Fungal endophytes have remarkable potential to produce a wide range of pharmacologically significant bioactive compounds that are used in disease management and human welfare. The principal gaps in the scientific literature on hyphomycetes as dietary supplements are: (1) the near-complete absence of human clinical trials for specific hyphomycete extracts (as opposed to the hyphomycete-derived pharmaceutical agents already in clinical use); (2) the lack of standardized extraction and quality control methods for supplement products; and (3) limited pharmacokinetic and bioavailability data for orally administered hyphomycete secondary metabolites.
Fungi are prolific producers of secondary metabolites and an important source of novel and commercially important pharmaceuticals, mycoinsecticides, and antibiotics. Fungi have been recognised as a prolific source of structurally unique secondary metabolites with promising pharmacological properties; comprehensive recent reviews summarise the chemical architectures, bioactivities, and research strategies for new fungal-derived natural products. The trajectory of research strongly supports continued investigation, but translation to validated dietary supplement applications with meaningful human evidence remains largely unrealized as of the date of this article.
Health conditions that Hyphomycetes may help support.
Body systems that Hyphomycetes may help support.
Go back